Vertex Pharmaceuticals (VRTX) has sparked a new round of anger among cystic fibrosis patients in the U.K. by requesting extra time to submit evidence for a new triple-combination therapy to a cost-effectiveness agency, a move that will likely delay availability by several months or more.

In explaining its decision, the drug maker wants time to submit more data, but the delay also allows it to take advantage of a change the U.K.’s National Institute for Health and Care Excellence is making in its process for assessing the value of medicines, which is expected to be finalized in June 2021. The changes are being made after the agency encountered criticism from both the pharmaceutical industry and patient groups over its approach to deciding value.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Viewing the entirety of the history here, Vertex reaffirms the belief that patients come last after patents, profits, bonuses and carefully crafted press releases.

    Not that Vertex is alone in this but it’s easy to understand why Big Pharma spends tens of millions to convince us of their alleged compassion.

    Many decent folks work day in and out in pharma for altruistic reasons and hats off to them. Thank you!

    Senior management, however, achieves their options grants and bonuses on very different terms – that such may be incompatible with expediting new drugs (to seriously afflicted patients) is the ugly truth.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy